• Publications
  • Influence
Some puzzling pharmacological effects of monoamine oxidase inhibitors.
  • J. Knoll, K. Magyar
  • Chemistry, Medicine
    Advances in biochemical psychopharmacology
  • 1972
The striatal dopamine dependency of life span in male rats. Longevity study with (−)deprenyl
  • J. Knoll
  • Medicine, Biology
    Mechanisms of Ageing and Development
  • 31 December 1988
TLDR
It is established by the aid of (-)deprenyl, a highly specific chemical tool, which increases superoxide dismutase activity in the striatum, facilitates the activity of the nigrostriatal dopaminergic neurons with utmost selectivity, and protects these neurons from their age-related decay, that the efficiency of a male rat in behavioral tests, as well as the duration of its life are striatal dopamine dependent functions.
The possible mechanisms of action of (-)deprenyl in Parkinson's disease
  • J. Knoll
  • Psychology, Medicine
    Journal of Neural Transmission
  • 2005
TLDR
The advantage of the combination of levodopa and (-)deprenyl in the treatment of Parkinson's disease was summarized as follows.
Evidence that acetylcholine released by gastrin and related polypeptides contributes to their effect on gastrointestinal motility.
TLDR
Gastrin- and cholecystokinin-like polypeptides may play a role as hormonal factors in regulating gastrointestinal motility, and their effect is continuously controlled by the tonic activity of the sympathetic nervous system which reduces acetycholine release.
(-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
  • J. Knoll
  • Medicine
    Pharmacology & toxicology
  • 1 February 1998
TLDR
It may be supposed that a prophylactic low dose administration of a safe catecholaminergic activity enhancer substance during the postdevelopmental phase of life will slow the age-related decline of behavioral performances, delay natural death and decrease susceptibility to Parkinson's disease and Alzheimer's disease.
Selective inhibition of the "B form" of monoamine oxidase.
  • K. Magyar, J. Knoll
  • Chemistry, Medicine
    Polish journal of pharmacology and pharmacy
  • 1 May 1977
TLDR
Deprenyl elevates the concentration of 3H-noradrenaline (3H-NA) in the synaptosomal fraction of rat heart homogenate while pargyline, probably due to its releasing effect, decreases 3 H-NA content in the same fraction.
Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study
TLDR
Results are interpreted as indicating l-deprenyl's ability to prevent or retard the degeneration of striatal dopaminergic neurons, the first anti-Parkinson drug having such a property.
(-)Deprenyl (Selegiline): past, present and future.
  • J. Knoll
  • Medicine
    Neurobiology
  • 23 October 2000
TLDR
It is reasonable to expect that a prophylactic low dose administration of a safe catecholaminergic activity enhancer substance during the postdevelopmental phase of life will slow the age-related decline of behavioral performances, delay natural death and decrease susceptibility to Parkinson's disease and Alzheimer's disease.
Novel (-)deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action.
TLDR
A structure-activity relationship study has revealed the importance of the aromatic ring and the optimum length of the chain between the aromatic rings and the nitrogen for the selective inhibition of MAO-B and HCl seems to be the most promising selective inhibitor.
...
1
2
3
4
5
...